Post-exposure therapy with recombinant human BuChE following percutaneous VX challenge in guinea-pigs

Toxicology Letters

Volumn 206, Issue 1, 2011, Pages 29-34

  Mumford, Helen ^a   Troyer, John K ^b  

^a Pharmacology and Behaviour Team   (United Kingdom)

^b PharmAthene Inc   (United States)

Author keywords

Bioscavenger; Guinea pig; Medical countermeasures; Nerve agent; Percutaneous; VX

Indexed keywords

CHOLINESTERASE; METHYLPHOSPHONOTHIOIC ACID S (2 DIISOPROPYLAMINOETHYL) O ETHYL ESTER; PROTEXIA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; BRADYCARDIA; CONTROLLED STUDY; ELECTROENCEPHALOGRAM; HEART RATE; HYPOTHERMIA; INTOXICATION; LOCOMOTION; NERVE AGENT POISONING; NONHUMAN; PRIORITY JOURNAL; SEIZURE; TELEMETRY;

ACETYLCHOLINESTERASE; ANIMALS; BIOCATALYSIS; BRAIN; BUTYRYLCHOLINESTERASE; CHEMICAL WARFARE AGENTS; CHOLINESTERASE REACTIVATORS; DRUG CARRIERS; ELECTRODES; ELECTROENCEPHALOGRAPHY; GUINEA PIGS; HUMANS; MALE; MOTOR ACTIVITY; ORGANOTHIOPHOSPHORUS COMPOUNDS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; SKIN; SKIN ABSORPTION; SURVIVAL ANALYSIS; TELEMETRY;

ANIMALIA; CAVIA;

EID: 80051812501     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2011.05.1016     Document Type: Article

References (25)

1. Allon N., Raveh L., Gilat E., Cohen E., Grunwald J., Ashani Y. Prophylaxis against soman inhalation toxicity in guinea pigs by pretreatment alone with human serum butyrylcholinesterase. Toxicol. Sci. 1998, 43:121-128.
2. Armstrong S.J., Graham S.J., Wetherell J.R., Troyer J.K. Recombinant butyrylcholinesterase as a post-poisoning therapy for percutaneous VX poisoning. Proceedings of the 16th Biennial Medical Defense Bioscience Review, vol. 140 2008.
3. Broomfield C.A., Maxwell D.M., Solana R.P., Castro C.A., Finger A.V., Lenz D.E. Protection by butyrylcholinesterase against organophosphorus poisoning in nonhuman-primates. J. Pharmacol. Exp. Ther. 1991, 259:633-638.
4. Castro C.A., Gresham V.C., Finger A.V., Maxwell D.M., Solana R.P., Lenz D.E., Broomfield C.A. Behavioral decrements persist in Rhesus-monkeys trained on a serial probe recognition task despite protection against soman lethality by butyrylcholinesterase. Neurotox. Teratol. 1994, 16:145-148.
5. Cerasoli D.M., Griffiths E.M., Doctor B.P., Saxena A., Fedorko J.M., Greig N.H., Yu Q.S., Huang Y., Wilgus H., Karatzas C.N., Koplovitz I., Lenz D.E. In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia (TM)) as a potential nerve agent bioscavenger. Chem. Biol. Interact. 2005, 157:363-365.
6. Dorandeu F., Foquin A., Briot R., Delacour C., Denis J., Alonso A. An unexpected plasma cholinesterase activity rebound after challenge with a high dose of the nerve agent VX. Toxicology 2008, 248:151-157.
7. Huang Y.-J., Huang Y., Baldassarre H., Wang B., Lazaris A., Leduc M., Bilodeau A.S., Bellemare A., Côté M., Herskovits P., Touati M., Turcotte C., Valeanu L., Lemee N., Wilgus H., Bégin I., Bhatia B., Rao K., Neveu N., Brochu E., Pierson J., Hockley D.K., Cerasoli D.M., Lenz D.E., Karatzas C.N., Langermann S. Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:13603-13608.
8. Huang Y.-J., Lundy P.M., Lazaris A., Huang Y., Baldassarre H., Wang B., Turcotte C., Côté M., Bellemare A., Bilodeau A.S., Brouillard S., Touati M., Herskovits P., Bégin I., Neveu N., Brochu E., Pierson J., Hockley D.K., Cerasoli D.M., Lenz D.E., Wilgus H., Karatzas C.N., Langermann S. Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin. BMC Biotechnol. 2008, 8:50.
9. Joosen M.J.A., van der Schans M.J., van Helden H.P.M. Percutaneous exposure to VX: clinical signs, effects on brain acetylcholine levels and EEG. Neurochem. Res. 2008, 33:308-317.
10. Katos M., Conti M.L., Moran T.S., Gordon R.K., Doctor B.P., Sciuto A.M., Nambiar M.P. Abdominal bloating and irritable bowel syndrome like symptoms following microinstillation inhalation exposure to chemical warfare nerve agent VX in guinea pigs. Toxicol. Ind. Health 2007, 23:231-240.
11. Lenz D.E., Broomfield C.A., Maxwell D.M., Cerasoli D.M. Nerve agent bioscavengers: protection against high- and low-dose organophosphorus exposure. Chemical Warfare Agents: Toxicity at Low Levels 2001, 245-260. CRC Press, Boca Raton. S. Somani, J.A. Romano (Eds.).
12. Lenz D.E., Maxwell D.M., Koplovitz I., Clark C.R., Capacio B.R., Cerasoli D.M., Federko J.M., Luo C.Y., Saxena A., Doctor B.P., Olson C. Protection against soman or VX poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys. Chem. Biol. Interact. 2005, 157:205-210.
13. Lenz D.E., Clarkson E.D., Schultz S.M., Cerasoli D.M. Butyrylcholinesterase as a therapeutic drug for protection against percutaneous VX. Chem. Biol. Interact. 2010, 187:249-252.
14. Mumford H., Lenz D.E., Cerasoli D.M., Price M.E., Graham S.J., Wetherell J.R. A preliminary assessment of pretreatment with human butyrylcholinesterase on the physiological effects of percutaneous VX challenge in the guinea-pig. Proceedings of the 16th Biennial Medical Defense Bioscience Review, vol. 43 2008.
15. Mumford H., Price M.E., Wetherell J.R. A novel approach to assessing percutaneous VX poisoning in the conscious guinea-pig. J. Appl. Toxicol. 2008, 28:694-702.
16. Mumford H., Price M.E., Cerasoli D.M., Teschner W., Ehrlich H., Schwarz H.P., Lenz D.E. Efficacy and physiological effects of human butyrylcholinesterase as a post-exposure therapy against percutaneous poisoning by VX in the guinea-pig. Chem. Biol. Interact. 2010, 187:304-308.
17. Mumford H., Price M.E., Lenz D.E., Cerasoli D.M. Post-exposure therapy with human butyrylcholinesterase following percutaneous VX challenge in guinea-pigs. Clin. Toxicol. 2011, 49:287-297.
18. Saxena A., Sun W., Dabisch P.A., Hulet S.W., Hastings N.B., Jakubowski E.M., Mioduszewski R.J., Doctor B.P. Efficacy of human serum butyrylcholinesterase against sarin vapor. Chem. Biol. Interact. 2008, 175:267-272.
19. Taysse L., Daulon S., Delamanche S., Bellier B., Breton P. Protection against soman-induced neuropathology and respiratory failure: a comparison of the efficacy of diazepam and avizafone in guinea-pig. Toxicology 2006, 225:25-35.
20. Tenn C.C., Mikler J.R., Hill I., Weatherby K., Garrett M., Caddy N., Stewart C., Karatzas C.N., Huang Y., Troyer J.K., Lundy P.M., Sawyer T.W. Recombinant human butyrylcholinesterase as a therapeutic agent to counteract the effects of VX toxicity in domestic swine. J. Med. Chem. Def. 2008, 6.
21. Vale J.A., Rice P., Marrs T.C. Managing civilian casualties affected by nerve agents. Chemical Warfare Agents: Toxicology and Treatment 2007, 249-260. John Wiley & Sons, Chichester. 2nd ed.
22. van der Schans M.J., Lander B.J., van der Wiel H., Langenberg J.P., Benschop H.P. Toxicokinetics of the nerve agent (+/-)-VX in anesthetized and atropinized hairless guinea pigs and marmosets after intravenous and percutaneous administration. Toxicol. Appl. Pharmacol. 2003, 191:48-62.
23. Wetherell J.R. Continuous administration of low-dose rates of physostigmine and hyoscine to guinea-pigs prevents the toxicity and reduces the incapacitation produced by soman poisoning. J. Pharm. Pharmacol. 1994, 46:1023-1028.
24. Wetherell J., Hall T., Passingham S. Physostigmine and hyoscine improves protection against the lethal and incapacitating effects of nerve agent poisoning in the guinea-pig. Neurotoxicology 2002, 23:341-349.
25. Wetherell J., Price M., Mumford H., Armstrong S., Scott L. Development of next generation medical countermeasures to nerve agent poisoning. Toxicology 2007, 233:120-127.